|
US20030044409A1
(en)
|
2001-05-01 |
2003-03-06 |
Carson Dennis A. |
Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
|
|
PL2157192T3
(pl)
|
2003-10-10 |
2014-01-31 |
Deutsches Krebsforsch |
Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
|
|
DE102004050620A1
(de)
|
2004-10-13 |
2006-04-20 |
Eberhard-Karls-Universität Tübingen |
Monoklonaler Antikörper gegen Frizzled-Rezeptoren
|
|
DE102005035568A1
(de)
|
2005-07-25 |
2007-02-01 |
M-Phasys Gmbh |
Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP2386577A3
(en)
|
2006-06-21 |
2012-05-02 |
Oncotherapy Science, Inc. |
Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
|
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
|
WO2008093646A1
(ja)
|
2007-02-01 |
2008-08-07 |
National University Corporation NARA Institute of Science and Technology |
Wntシグナル伝達系活性化ペプチド
|
|
SG190568A1
(en)
|
2008-09-26 |
2013-06-28 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
EP2412800A1
(en)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Liver organoid, uses thereof and culture method for obtaining them
|
|
EP2393917B1
(en)
|
2009-02-03 |
2016-04-06 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising said stem cells.
|
|
WO2010092457A1
(en)
|
2009-02-10 |
2010-08-19 |
Nokia Corporation |
Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
|
|
EP2305274A1
(en)
|
2009-09-21 |
2011-04-06 |
Centre National de la Recherche Scientifique (CNRS) |
Use of WNT stimulators for treating demyelinating diseases
|
|
AU2010329904B2
(en)
|
2009-12-09 |
2015-07-09 |
Bayer Pharma Aktiengesellschaft |
Anti-C4.4a antibodies and uses thereof
|
|
CA2794674A1
(en)
|
2010-04-01 |
2011-10-06 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
|
US8802438B2
(en)
|
2010-04-16 |
2014-08-12 |
Children's Medical Center Corporation |
Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
EP3460064B8
(en)
|
2011-04-03 |
2024-03-20 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Efficient protein expression in vivo using modified rna (mod-rna)
|
|
GB201106395D0
(en)
|
2011-04-14 |
2011-06-01 |
Hubrecht Inst |
Compounds
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
WO2013054307A2
(en)
*
|
2011-10-14 |
2013-04-18 |
Novartis Ag |
Antibodies and methods for wnt pathway-related diseases
|
|
WO2013071047A1
(en)
|
2011-11-11 |
2013-05-16 |
Children's Medical Center Corporation |
Compositions and methods for in vitro transcription of rna
|
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
|
ES2797533T3
(es)
|
2012-02-28 |
2020-12-02 |
Novartis Ag |
Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
CA2878626A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
US20160022840A1
(en)
|
2013-03-09 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
CN106714831A
(zh)
|
2014-04-21 |
2017-05-24 |
艾伯维施特姆森特克斯有限责任公司 |
新的抗‑rnf43抗体和使用方法
|
|
AU2015314771B2
(en)
|
2014-09-12 |
2021-04-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Wnt signaling agonist molecules
|
|
KR20170075778A
(ko)
|
2014-10-27 |
2017-07-03 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
항-tim-3 항체
|
|
WO2016073906A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related immunoassays
|
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
JP2018513155A
(ja)
|
2015-04-17 |
2018-05-24 |
メリマック ファーマシューティカルズ インコーポレーティッド |
セリバンツマブを用いた併用療法
|
|
SMT202100230T1
(it)
*
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
DK3386534T3
(da)
|
2015-12-08 |
2020-11-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
US20170349659A1
(en)
|
2016-06-03 |
2017-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Wnt signaling agonist molecules
|
|
TN2019000164A1
(en)
*
|
2016-11-23 |
2020-10-05 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
WO2018107116A1
(en)
|
2016-12-09 |
2018-06-14 |
Abbvie Stemcentrx Llc |
Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
|
|
US11993645B2
(en)
|
2017-01-11 |
2024-05-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions comprising R-Spondin (RSPO) surrogate molecules
|
|
WO2018140821A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses thereof
|
|
WO2018203567A1
(en)
|
2017-05-02 |
2018-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
GB201708330D0
(en)
|
2017-05-24 |
2017-07-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Fusion protein for enhancing intestinal regeneration
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
CN117946267A
(zh)
|
2017-12-19 |
2024-04-30 |
瑟罗泽恩奥普瑞汀公司 |
抗卷曲蛋白抗体和使用方法
|
|
US20210292422A1
(en)
|
2018-07-05 |
2021-09-23 |
Surrozen, Inc. |
Multi-specific wnt surrogate molecules and uses thereof
|
|
CA3104868A1
(en)
|
2018-07-09 |
2020-01-16 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses thereof
|
|
WO2020132356A1
(en)
|
2018-12-19 |
2020-06-25 |
Surrozen, Inc. |
Antigen binding formats for receptor complexes
|
|
EP3924381A4
(en)
|
2019-02-11 |
2023-07-26 |
Surrozen Operating, Inc. |
MODULATION OF WNT SIGNALING IN EYE DISEASES
|
|
EP3938036A4
(en)
|
2019-03-11 |
2023-06-28 |
Surrozen Operating, Inc. |
Modulation of wnt signaling in gastrointestinal disorders
|
|
US20220175884A1
(en)
|
2019-04-02 |
2022-06-09 |
Surrozen Operating, Inc. |
Modulation of wnt signaling in auditory disorders
|
|
JP7377288B2
(ja)
|
2019-06-11 |
2023-11-09 |
アントレラ セラピューティクス インコーポレイテッド |
多価ｆｚｄおよびｗｎｔ結合分子とその使用
|
|
US11050604B2
(en)
|
2019-07-01 |
2021-06-29 |
Rampart Communications, Inc. |
Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
|
|
CA3170340A1
(en)
|
2020-02-24 |
2021-09-02 |
Surrozen Operating, Inc. |
Wnt super agonists
|
|
JP2023549854A
(ja)
|
2020-11-16 |
2023-11-29 |
スロゼン オペレーティング， インコーポレイテッド |
肝臓特異的Ｗｎｔシグナル増強分子およびその使用
|
|
WO2022192445A1
(en)
|
2021-03-10 |
2022-09-15 |
Surrozen Operating, Inc. |
Modulation of wnt signaling in gastrointestinal disorders
|
|
CA3229303A1
(en)
|
2021-09-14 |
2023-03-23 |
Russell FLETCHER |
Modulation of wnt signalling in pulmonary disorders
|
|
AU2022413699A1
(en)
|
2021-12-17 |
2024-07-04 |
Surrozen Operating, Inc. |
Wnt-surrogate agents and methods for lacrimal gland regeneration
|